Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
IsoEnergy (T.ISO) Announces Acquisition of Anfield Energy (V.AEC) (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Merck & Co Inc V.MRK


Primary Symbol: MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products include therapeutic and preventive agents, sold by prescription, for the treatment of human disorders. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3, an inhibitory canonical Notch ligand. Its lead candidate, Restoret, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway.


NYSE:MRK - Post by User

Merck & Co Inc > Something must be wrong???
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by Salvadoralon Aug 13, 2010 12:56pm
152 Views
Post# 17348863

RE: Something must be wrong???

RE: Something must be wrong???The market just dosen't care right now. I have a couple of other juniors that have reported stellar results with no market reaction. We are just heading into Gold Seasonality so hope things will change especially if Gold heads to $1500.00 as some exerts predict. Big time insider buying to end of Apr at .195 to .255 so that should tell us something. Good luck. Salvadoral
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities